MC

519.7

-1.33%↓

SANES

10.204

-3.43%↓

BBVA

19.365

-3.8%↓

BNP

89.47

-4.7%↓

CABK

10.21

-5.24%↓

MC

519.7

-1.33%↓

SANES

10.204

-3.43%↓

BBVA

19.365

-3.8%↓

BNP

89.47

-4.7%↓

CABK

10.21

-5.24%↓

MC

519.7

-1.33%↓

SANES

10.204

-3.43%↓

BBVA

19.365

-3.8%↓

BNP

89.47

-4.7%↓

CABK

10.21

-5.24%↓

MC

519.7

-1.33%↓

SANES

10.204

-3.43%↓

BBVA

19.365

-3.8%↓

BNP

89.47

-4.7%↓

CABK

10.21

-5.24%↓

MC

519.7

-1.33%↓

SANES

10.204

-3.43%↓

BBVA

19.365

-3.8%↓

BNP

89.47

-4.7%↓

CABK

10.21

-5.24%↓

Search

Sartorius Stedim Biotech.

Atidarymo kaina

SektoriusFinansų sektorius

173.1 0.93

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

168.2

Max

174.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-28M

64M

Pardavimai

67M

772M

P/E

Sektoriaus vid.

66.019

26.803

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

9.097

Darbuotojai

10,134

EBITDA

555M

772M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+32.13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-877M

17B

Ankstesnė atidarymo kaina

172.17

Ankstesnė uždarymo kaina

173.1

Naujienos nuotaikos

By Acuity

63%

37%

379 / 444 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-12 23:57; UTC

Karštos akcijos

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026-02-12 23:35; UTC

Uždarbis
Pagrindinės rinkos jėgos

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026-02-12 23:28; UTC

Uždarbis

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026-02-12 21:47; UTC

Uždarbis

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026-02-13 00:00; UTC

Rinkos pokalbiai

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026-02-12 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026-02-12 23:38; UTC

Rinkos pokalbiai

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026-02-12 23:33; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026-02-12 23:09; UTC

Rinkos pokalbiai

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026-02-12 22:55; UTC

Uždarbis
Karštos akcijos

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026-02-12 22:46; UTC

Rinkos pokalbiai

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026-02-12 22:23; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026-02-12 21:57; UTC

Uždarbis

XP 4Q Rev BRL4.95B >XP

2026-02-12 21:52; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-12 21:47; UTC

Uždarbis

Morningstar 4Q Rev $641M >MORN

2026-02-12 21:39; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:38; UTC

Uždarbis

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

32.13% į viršų

12 mėnesių prognozė

Vidutinis 235.86 EUR  32.13%

Aukščiausias 260 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

3

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

379 / 444 reitingas Finansų sektorius

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat